Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase

AIDS, Supplement

Volumn 10, Issue 5, 1996, Pages

  Wainberg, Mark A ^a,b   Hsu, Mayla ^a   Gu, Zhengxian ^a   Borkow, Gadi ^a   Parniak, Michael A ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

3TC; Fidelity; HIV resistance; HIV reverse transcriptase; Monotherapy

Indexed keywords

ANTIVIRUS AGENT; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; VIRUS ENZYME;

CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS MUTANT; VIRUS RESISTANCE;

EID: 0030512725     PISSN: 13502840     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199612005-00002     Document Type: Conference Paper

References (53)

1. Takeuchi Y, Nagumo T, Hoshino H: Low fidelity of cell free DNA synthesis by reverse transcriptase of human immunodeficiency virus. J Virol 1988, 62:3900-3902.
2. Roberts JD, Bebenek K, Kunkel TA: The accuracy of reverse transcriptase from HIV-1. Science 1988, 242:1171-1173.
3. Preston BD, Poiesz BJ, Loeb LA: The fidelity of HIV-1 reverse transcriptase. Science 1988, 242:1168-1171.
4. Larder BA, Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989, 246:1155-1158.
5. Fitzgibbon JE, Howell RM, Haberzettl CA, Sperber SJ, Gocke DJ, Dubin DT: Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob Agents Chemother 1992, 36:153-157.
6. St Clair MH, Martin JL, Tudor-Williams C, et al.: Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991, 253:1557-1559.
7. Zhang D, Caliendo AM, Eron JJ, et al.: Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1994, 38:282-287.
8. Pillay D, Bryant M, Gutman D, Richman DD: HIV-1 protease inhibitors: their development, mechanism of action and clinical potential. Rev Med Virol 1995, 5:23-33.
9. Richman DD, Havlir D, Corbeil J, et al.: Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994, 68:1660-1666.
10. Wolfs TFW, dejong JJ, Van den Berg H, et al.: Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous. Proc Natl Acad Sci USA 1990, 87:9938-9942.
11. Page KA, Stearns SM, Littman DR: Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity. J Virol 1992, 66:524-533.
12. de Jong JJ, Goudsmit J, Keulen W, et al.: Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol 1992, 66:757-765.
13. Schuitemaker H, Kootstra NA, de Goede RE, et al.: Monocytotropic human immunodeficiency virus 1 (HIV-1) variants detected in all stages of HIV infection predominantly with T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J Virol 1991, 65:356-363.
14. Boucher CAB, Lange JMA, Miedema FF, et al.: HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992, 6:1259-1264.
15. Battula N, Loeb LA: On the fidelity of DNA replication. Lack of exodeoxyribonuclease activity and error-correcting function in avian myeloblastosis virus DNA polymerase. J Biol Chem 1976, 251:982-986.
16. Larder BA, Darby G, Richman DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989, 243:1231-1234.
17. Nunberg JH, Schleif WA, Boots EJ, et al.: Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol 1991, 65:4887-4892.
18. Rooke R, Tremblay M, Soudeyns H, et al.: Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine (AZT) therapy. Canadian Zidovudine Multi-Centre Study Group. AIDS 1989, 3:411-415.
19. Tudor-Williams G, St Clair MH, McKinney RE, et al.: HlV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 1992, 339:15-19.
20. D'Aquila RT, Johnson VA, Welles SC, et al.: Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med 1995, 122:401-408.
21. 3. Ann Intern Med 1995, 123:561-571.
22. Montaner JSG, Singer J, Schechter MT, et al.: Clinical correlates of in vitro HIV-1 resistance of zidovudine: results of the Multicentre Canadian AZT Trial. AIDS 1993, 7:189-196.
23. Katlama C, Ingrand D, Loveday C et al.: Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: a randomized controlled comparison with zidovudine monotherapy. JAMA 1996, 276:118-125.
24. Staszewski S, Loveday C, Picazo JJ, et al.: Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients: a randomized controlled comparison with zidovudine monotherapy. JAMA 1996, 276:111-117.
25. Eron JJ, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995, 333: 1662-1669.
26. Tisdale M, Kemp SD, Parry NR, Larder BA: Rapid in vitro selection of human immunodeficiency virus type 1 resistance to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90: 5653-5656.
27. Boucher CAB, Cammack N, Schipper P, et al.: High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993, 37:2231-2234.
28. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
29. Gu Z, Gao Q, Li X, Parniak MA, Wainberg MA: A novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes resistance to 2′,3′-dideoxyinosine and cross-resistance to 2′,3′-dideoxycytidine. J Virol 1992, 66:7128-7135.
30. Schinazi RF, Lloyd RM Jr, Nguyen M-H, et al.: Characterisation of human immunodeficiency viruses resistant to oxathiolanecytosine nucleosides. Antimicrob Agents Chemother 1993, 42:825-830.
31. Gao Q, Gu Z, Parniak MA, et al.: The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-)enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993, 37:1390-1392.
32. Schuurman R, Nijhuis M, van Leeuwen R, et al.: Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995, 171:1411-1419.
33. Wainberg MA, Salomon H, Montaner JSG, et al.: Development of human immunodeficiency virus type 1 resistance to 2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex (ARC). AIDS 1995, 9:351-357.
34. Pluda J, Cooley TP, Montaner JSG, et al.: A phase I/II study of 2′-deoxy-3′-thiacytidine in patients with advanced human immunodefiency virus infection. J Infect Dis 1995, 171:1438-1447.
35. Lewis LL, Venzon D, Church J, et al.: Lamivudine (3TC) in children with HIV infection: A phase I/II study. J Infect Dis 1996, 174:16-25.
36. Salomon H, Belmonte A, Nguyen K, et al.: Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1. J Clin Microbiol 1994, 32:2000-2002.
37. Japour AJ, Mayers DL, Johnson VA, et al.: Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1993, 37:1095-1101.
38. Gu Z, Gao Q, Fang H, et al.: Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′- dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1994, 38:275-281.
39. Arts EJ, Li X, Gu Z, et al.: Comparison of deoxyoligonucleotide and tRNALys3 as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. J Biol Chem 1994, 269:14672-14680.
40. Arts EJ, Mak J, Kleiman L, Wainberg MA: DNA found in human immunodeficiency virus type 1 particles may not be required for infectivity. J Gen Virol 1994, 75:1605-1613.
41. Conrad AJ, Schmid P, Syndulko K, et al.: Quantifying HIV-1 RNA using polymerase chain reaction (PCR) on cerebrospinal fluid (CSF) and serum of seropositive individuals with and without neurologic abnormalities. J AIDS 1995, 10:425-435.
42. Tremblay M, Wainberg MA: Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J Infect Dis 1990, 162:735-737.
43. Weber JN, Weiss RA, Roberts C, et al.: Human immunodeficiency virus infection in two cohorts of homosexual men: neutralizing sera and association of anti-GAG antibody with prognosis. Lancet 1987, i:119-121.
44. Prince AM, Pascual D, Kosolapov LB, et al.: Prevalence, clinical significance, and strain specificity of the neutralizing antibody of the human immunodeficiency virus. J Infect Dis 1987, 156:268-272.
45. Gu Z, Fletcher RS, Arts EJ, et al.: The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-3′-thiacytidine and 2′,3′-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J Biol Chem 1994, 269:28118-28123.
46. Gu Z, Arts EJ, Parniak MA, Wainberg MA: Mutated K65R recombinant HIV-1 reverse transcriptase shows diminished chain termination in the presence of 2′,3′-dideoxycytidine-5′-triphosphate and other drugs. Proc Natl Acad Sci USA 1995, 92:2760-2764.
47. Kohlstaedt LA, Wang J, Friedman J, et al.: Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256:1783-1790.
48. Jacobo-Molina A, Ding J, Nanni RG, et al.: Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3 A resolution shows bent DNA. Proc Natl Acad Sci USA 1993, 90:6320-6324.
49. Wainberg MA, Drospoulos WC, Salomon H, et al.: Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996, 271:1282-1285.
50. Pandey VN, Kaushik N, Rege N, et al.: Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis. Biochemistry 1996, 35:2168-2179.
51. Drospoulos WC, Prasad VR: Increased polymerase fidelity of E89G, a nucleoside analog-resistant variant of human immunodeficiency virus type 1 reverse transcriptase. J Virol 1996, 70: 4834-4838.
52. Kew Y, Salomon H, Olsen LR, et al.: The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 displays a broader cross-resistance that extends to nonnucleoside inhibitors. Antimicrob Agents Chemother 1996, 40:1711-1714.
53. Boyer PL, Hughes SH: Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1995, 39:1624-1628.